Nepexto (Etanercept)

Etanercept, the active ingredient in Nepexto, is a TNF-alpha inhibitor presented as a subcutaneous injection for subcutaneous use. It treats rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and juvenile idiopathic arthritis in appropriate patient populations.

GNH USA supplies Nepexto as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nepexto (etanercept) is a TNF‑alpha inhibitor used in several inflammatory and autoimmune disease categories.

Rheumatoid arthritis: reduces joint inflammation, pain and structural damage. Psoriatic arthritis: improves joint symptoms and skin lesions. Ankylosing spondylitis: decreases spinal inflammation and improves mobility. Plaque psoriasis: lessens skin plaque formation and severity. Juvenile idiopathic arthritis: controls disease activity and prevents joint damage.

Etanercept may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain, redness or swelling. - Upper respiratory tract infection. - Headache. - Nausea. - Fatigue.

Serious or Rare Side Effects: - Serious infections such as tuberculosis or bacterial sepsis. - Malignancies including lymphoma or skin cancer. - Demyelinating disorders like multiple sclerosis. - New or worsening heart failure. - Lupus‑like syndrome. - Cytopenias (low blood cell counts).

Before initiating etanercept therapy, several precautionary measures should be considered to ensure patient safety.

Screen for active infections: evaluate for tuberculosis and other serious infections before starting treatment. Monitor for signs of infection: advise patients to report fevers, cough, or unusual symptoms promptly. Assess cardiac status: avoid use in patients with uncontrolled heart failure. Check for demyelinating disease: discontinue if neurological symptoms suggest demyelination. Vaccination considerations: avoid live vaccines during treatment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Etanercept can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live attenuated vaccines: may cause infection. - Concurrent use with other biologic immunosuppressants: heightened infection risk. - Severe active infection: therapy should be withheld.

Moderate Interactions (Monitor Closely): - Methotrexate or other DMARDs: may increase immunosuppression. - Azathioprine, cyclosporine, or tacrolimus: monitor blood counts and liver function. - Non‑live vaccines: may have reduced efficacy, schedule appropriately. - Antifungal agents (e.g., azoles): observe for additive immunosuppression.